Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Plexpress Secures $2.3M to Commercialize TRAC High-Content Gene Expression Analysis Platform

Published: Thursday, April 19, 2012
Last Updated: Thursday, April 19, 2012
Bookmark and Share
Company targets applications including companion diagnostics and ADMET.

Plexpress has announced follow-on funding of up to $2.3M to commercialize its novel TRAC (Transcript Analysis with the aid of Affinity Capture) platform for high-content gene expression analysis.

The investment has been secured to commercialize the technology internationally, build up the ADMET screening service and develop TRAC specifically within the oncology sector.

Existing investors - Conor Technology Fund, VTT Ventures, Aloitusrahasto Vera and the Helsinki University Fund - as well as Tekes, the Finnish Funding Agency for Technology and Innovation, have invested $1.4M initially with further milestone payments of up to $900k.

As the potential applications and opportunities in genomic research continue to grow, the TRAC system is poised to provide the ideal method for the increased throughput and multiplex screening that the development of new therapies and diagnostics requires.

With TRAC, the expression of up to 30 genes can be routinely quantified in each plate well (30-plex), while thousands of samples can be processed quickly, easily and reproducibly.

The TRAC technology has been refined and validated over 10 years of development, initially at the Technical Research Centre of Finland, VTT, and subsequently at Plexpress, with over 50 separate projects completed successfully.

By avoiding the need for RNA extraction, cDNA conversion and amplification, the TRAC protocol takes only four hours to complete and RNA degradation is significantly reduced. This makes it fast, simple and cost-effective to implement, while lowering error rates and maximizing accuracy.

“This funding will enable Plexpress to pursue high value market opportunities, such as companion diagnostics and ADMET. TRAC provides significant benefits over existing technologies such as qPCR and microarrays, which do not offer either the throughput or the multiplexing that many genomics researchers require. Our early investors recognized these opportunities and have underlined their belief in TRAC with this continuing funding”, said Plexpress CEO, and leading expert in TRAC technology, Dr Jari Rautio.

Commenting on the renewed funding, MoB Managing Partner, Jari Mieskonen, of Conor Venture Partners said: “We are very happy that all current investors continued to support Plexpress in this follow-on investment round. The added involvement of Tekes gives us increased leverage for commercializing the TRAC technology and with the extremely positive feedback from key customers we foresee a fast market roll-out.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Blood-brain Barrier on a Chip
Researchers from Vanderbilt University have developed a microfluidic device to study the blood-brain barrier.
Genetic Links to Brain Cancer Cell Growth
Researchers discover clues to tumour behaviour from genetic differences between brain cancer cells and normal tissue cells.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Secret Phenotypes: Disease Devils in Invisible Details
Algorithmic deep phenotyping exposes masses of hidden traits and possible subtle genetic connections relevant to unseen influences on disease.
Hunting the Missing Link Between Genetics and the Environment
The International Phenome Centre Network (IPCN) works to transform healthcare through phenomics - the dynamic interactions between our genes and our environment.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!